We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 19, 2021

Intermittent vs Continuous Administration of Pazopanib in Progressive Radioiodine-Refractory Thyroid Carcinoma

European Journal of Cancer


Additional Info

European Journal of Cancer
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Eur. J. Cancer 2021 Sep 09;157(xx)153-164, C de la Fouchardière, Y Godbert, C Dalban, F Illouz, J Wassermann, C Do Cao, S Bardet, S Zerdoud, CN Chougnet, M Zalzali, D Benisvy, P Niccoli, L Digue, L Lamartina, P Schwartz, F Borson Chazot, J Gautier, D Pérol, S Leboulleux,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading